



**CAC2**  
COALITION AGAINST  
CHILDHOOD CANCER

Celebrating 10 Years of Serving the Childhood Cancer Community



# CAC2 Annual Summit

**JUNE 19-21, 2023**

Aflac Cancer and Blood Disorders Center  
of Children's Healthcare of Atlanta

We deliver care worthy of a future monarch,  
“because every child deserves a lifetime”

—Doug Graham, MD, PhD

**Aflac**  
Cancer & Blood  
Disorders Center  
**Children's**  
—Healthcare of Atlanta—



Copyright 2023 Childrens Healthcare of Atlanta.

## CAC2 Members,

**On behalf of the Aflac Cancer and Blood Disorders Center, welcome to the 2023 Coalition Against Childhood Cancer Summit. We are honored to host you in Atlanta and welcome you to the Peach State, home of Children’s Healthcare of Atlanta and Emory University.**

As one of the most active institutions in the U.S. in regard to pediatric clinical trial enrollment, we strive to improve and enhance the quality of life for our patients by offering some of the most promising new cancer agents and treatments for children who have relapse, or who have difficult-to-treat-cancers. It’s only through discovery, innovation, and collaboration that we’re able to find safer, more effective methods of treatment for our patients.

At the Aflac Cancer and Blood Disorders Center we are recognized as a national leader in clinical care and outcomes for children, adolescents and young adults with pediatric cancers and blood disorders because we focus on three key areas:

- **Multi-disciplinary, family-focused and equitable clinical care**
- **Innovative research to promote ground-breaking discovery leading to improved treatment and outcomes**
- **Teaching for providers, patients, families and the community**

We compassionately treat each child’s unique needs and develop a special treatment plan for the child and the whole family – starting from day one.

We are deeply humbled by your commitment to advancing research and treatment options for the children who are patients today and those who are not yet diagnosed.

Thank you for believing as we do, that every child deserves a lifetime.

Sincerely,


**DOUGLAS K. GRAHAM, MD, PhD**

Professor of Pediatrics  
William G. Woods, M.D. Chair  
Chief, Aflac Cancer and Blood Disorders Center  
Children’s Healthcare of Atlanta  
Division Chief, Pediatric Hematology/Oncology/BMT  
Emory University School of Medicine



# Let's imagine a world without childhood cancers.

The mission of the Coalition Against Childhood Cancer (CAC2) is to foster and sustain greater levels of collaboration, information exchange, and learning across the childhood cancer community through agreed upon initiatives in the areas of advocacy & awareness building, family support & survivorship, and research & treatment.



**Our most closely held shared value is to put children with cancer and their families first in everything we do.**

CAC2 members fund research and support families throughout the continuum of care of the childhood and adolescent cancer experience. CAC2 helps the childhood cancer community and the children and families it serves by:

- Leveraging the unique strengths of its members;
- Minimizing waste of precious resources and expertise; and
- Helping to drive better outcomes for patients and their families.

CAC2 designs and implements collaborative programs that allow our members to achieve goals that would otherwise be beyond their reach, ultimately increasing their impact on improving the lives of children and teens with cancer and their families.

# Welcome to the 2023 CAC2 Annual Summit!



## Dear CAC2 Members, Speakers, Panelists, and Guests:

I am thrilled to welcome you to the 2023 CAC2 Annual Summit! I have been particularly eager for this year's gathering, not only because I get to support you as CAC2's new Executive Director but also because our beloved coalition is turning 10 – a grand milestone that I'm overjoyed to experience with all of you.

In honor of our 10 years of collaboration, we will enjoy a special dinner together as well as spend the next 2 days learning from a truly accomplished group of speakers on important topics such as survivorship, mental health, clinical trial design, data integration, combination drug studies, immunotherapy, and nutrition.

Regardless of your background or interests, there is always something for everyone at the CAC2 Annual Summit. I hope you soak in all the new information; create meaningful new friendships and partnerships; and, most importantly, return home feeling hopeful about our children's futures.

As a mom of a young childhood cancer survivor, I deeply value each of you. Your decision to spend your precious time at this summit is greatly appreciated. I'm grateful for your passion, desire to collaborate, and your heart to give. I salute you and look forward to supporting you as CAC2 continues to grow and create a stronger network of individuals, nonprofits, and organizations all united against childhood cancer.

With gratitude,

MELISSA JACKSON

Executive Director  
Coalition Against Childhood Cancer (CAC2)

**PS. Don't forget to tag us in your posts to raise awareness about this year's CAC2 Annual Summit!**

#CAC2Summit2023



@cac2org



@CoalitionAgainstChildhoodCancer








linkedin.com/company/coalition-against-childhood-cancer



# 2023 Annual Summit

## MONDAY, JUNE 19, 2023

- 12:00 PM** Meeting Registration + Networking
- 1:00 PM** Summit Welcome from CAC2 and CHOA
- 1:30 PM** **Keynote #1 – Immunotherapy for Pediatric Cancers: A Review of Progress to Date and a Look Ahead**  
**RESEARCH & TREATMENT** **SURVIVORSHIP**  
Theodore W. Laetsch, MD, Director, Developmental Therapeutics Program; Director, Very Rare Malignant Tumors Program; Associate Professor of Pediatrics Children’s Hospital of Philadelphia and University of Pennsylvania
- 2:15 PM**  Movement break
- 2:30 PM** **Interactive Session #1 – Innovations in Survivorship Care**  
**FAMILY SUPPORT** **SURVIVORSHIP**  
Karen Effinger, MD, MS, Associate Professor of Pediatrics; Medical Director, Cancer Survivor Program Emory University and Children’s Healthcare of Atlanta
- 3:30 PM**  Movement break
- 3:45 PM** **Interactive Session #2 – Nutrition and Cancer: Feeding Through Treatment**  
**RESEARCH & TREATMENT** **SURVIVORSHIP**  
Kaleigh Nix, MS, RD, CSO, LD & Alyssa Withee, RD, LD, CSP  
Clinical Nutritionists, Children’s Healthcare of Atlanta
- 4:45 PM** Day 1 Summit Summary
- 5:00 PM**  Reception + Networking
- 6:30 PM**  Dine around dinner event (optional) or dinner on your own



### LAUNCHING THIS SEPTEMBER!

## Guidance Along the Survivorship Journey

Providing education and resources for childhood cancer survivors and families in six key areas:

- Educational Guidance and Planning
- Psychosocial/Emotional Health
- Insurance and Financial Health
- Transitioning to Adulthood
- Managing Physical Health and Late Effects
- Wellness/Healthy Behaviors



**Help Spread the Word!** Visit our table to **LEARN MORE.**



# Program Schedule

## TUESDAY, JUNE 20, 2023

**8:00 AM** Breakfast + Networking

**9:00 AM** **Panel Discussion – Transitioning Off Treatment for Lifetime Health**

ADVOCACY AWARENESS RESEARCH & TREATMENT FAMILY SUPPORT SURVIVORSHIP

Moderator: Mary Beth Collins, Parent Advocate, CAC2

- Panelists:
- Physician – ZoAnn E. Dreyer, MD, Sidney L. and Donald F. Faust Professor in Pediatric Cancer Survivorship; Clinical Director, Long-Term Survivor Program; Professor, Department of Pediatrics, Section of Hematology-Oncology; Texas Children's Hospital and Baylor College of Medicine
  - Patient Survivor – Lee Troutman

**10:15 AM**  Movement Break

**10:30 AM** **Lecture #1 – What's New in the Design of Clinical Trials for Children with Cancer?**

ADVOCACY RESEARCH & TREATMENT

Elizabeth Fox, MD, Senior Vice President, Clinical Research Administration; Associate Director of Clinical Research, St Jude Children's Research Hospital

**11:15 AM** **Lecture #2 – Early Phase Combination Drug Studies in Pediatric Oncology**

ADVOCACY RESEARCH & TREATMENT

Thomas Cash, MD, MSc, Associate Professor of Pediatrics & Director, Solid Tumor Program Emory University and Aflac Cancer & Blood Disorders Center, Children's Healthcare of Atlanta

**12:00 PM**  Group Photo

**12:05 PM**  Lunch + Networking

**1:15 PM** Welcome from CAC2's Executive Director

**1:45 PM** **Coffee and Collaboration**

**3:00 PM**  Movement Break

**3:15 PM** **Lecture #3 – NCI Childhood Cancer Research Update**

ADVOCACY AWARENESS RESEARCH & TREATMENT FAMILY SUPPORT SURVIVORSHIP

Jack F. Shern, MD, Lasker Clinical Research Scholar, Pediatric Oncology Branch, National Cancer Institute

**4:00 PM** **Lecture #4 – Childhood Cancer Awareness and Advocacy: A Review of Recent Achievements and a Look Ahead**

ADVOCACY AWARENESS

Vickie Buenger, BA, MA, PhD  
President Emeritus, CAC2

Susannah E. Koontz, PharmD, BCOP, FHOPA  
Principal, Koontz Oncology Consulting LLC

**5:00 PM** Day 2 Summit Summary

**5:15 PM** Break

**6:30 PM**  **CAC2 10th Anniversary Celebration Dinner**

## WEDNESDAY, JUNE 21, 2023



### 7:30-8:15 AM | A Personalized Approach to Care

Health Science Research Building Auditorium/Café

Daniel Wechsler, MD, PhD, Section Director of Oncology & Co-Director, Aflac Precision Medicine Program  
Ryan Summers, MD, Director of Molecular Tumor Board, Aflac Precision Medicine Program

The Aflac Precision Medicine Program (APMP) at Children's Healthcare of Atlanta leverages genomic sequencing for pediatric patients with high-risk tumors to identify alterations that can impact therapies and improve outcomes. Our pediatric specialists are developing novel, cutting-edge research approaches to enhance the safety and efficacy of personalized medical treatments. Pediatric cancer treatments historically have employed a "one-size-fits-all" approach in which disease treatment strategies were developed for the average patient, with less consideration for the significant differences across individual patients. The APMP utilizes genetic testing methods to identify specific changes in the DNA and RNA of cancer cells and offers individualized treatment options to our pediatric cancer patients. Sometimes, different treatments can precisely target cancer cells with these changes.

8:00 AM Breakfast + Networking

### 8:45 AM Keynote #2 – Addressing Caregiver Mental Health in Pediatric Oncology

AWARENESS FAMILY SUPPORT SURVIVORSHIP

Christina Salley, PhD, Director of Clinical Engagement & Outreach, Courageous Parents Network, Clinical Assistant Professor, Hassenfeld Children's Hospital & Department of Child & Adolescent Psychiatry, New York University School of Medicine

9:30 AM CAC2 Business Meeting

11:00 AM Movement Break

11:15 AM Team Time Working Lunch

1:00 PM Movement Break

1:15 PM Collaboration Work Plans + Summit Wrap-up

2:00 PM Summit Concludes

2:00-4:00 PM Laboratory Tours (optional)



Regardless of where you are on your survivorship journey, you are not alone.

Better Together: Survivorship Connection (BTSC) is a FREE, searchable collection of organizations focused on the needs and challenges of childhood cancer survivors.



Stop by the Better Together table to learn more about this exciting project.



# KIDS ARE DIFFERENT.

Their cancer treatments should be different too.



Jude,  
leukemia  
survivor

**Introducing the Dare to Dream Project.**  
Transforming treatment and care for kids  
with blood cancer.



LEUKEMIA &  
LYMPHOMA  
SOCIETY®

**DARETODREAM**  
PROJECT

[www.LLS.org/daretodream](http://www.LLS.org/daretodream)

The Focused Ultrasound Foundation  
is dedicated to accelerating the  
development and adoption of  
focused ultrasound.

We have established a  
**Pediatrics Program** to  
explore the potential of  
this technology for the  
younger population  
through support of  
laboratory studies,  
clinical trials, and  
expanded regulatory  
approvals.

To learn more, visit  
[fusfoundation.org](http://fusfoundation.org)



FOCUSED  
ULTRASOUND  
FOUNDATION



Day One is proud  
to support the  
CAC2 Hope Portal



©2023 Day One Biopharmaceuticals, Inc. PLGG-US-0110 05/23  
The Day One logo is a registered trademark of  
Day One Biopharmaceuticals, Inc. All rights reserved.



# Speakers & Panelists



## **Vickie Buenger**

President Emeritus, Coalition Against Childhood Cancer | Bryan, TX

Vickie Buenger recently retired as Clinical Professor at the Mays Business School at Texas A&M University with a joint appointment to the Professional Program for Biotechnology where she taught competitive and cooperative business strategy and project management. Vickie's daughter, Erin, fought neuroblastoma for 7 years. After Erin's death in 2009, Vickie devoted time and energy to launching the Coalition Against Childhood Cancer (CAC2) on behalf of the many dedicated organizations and individuals striving to make a difference for children with cancer. She currently serves as President Emeritus of CAC2 and combines her academic background with her interest in the science and policy of childhood cancer, speaking regularly before gatherings of scientists, clinicians, regulators, industry representatives, and advocates in the US and Europe.



## **Thomas Cash, MD, MSc**

Associate Professor of Pediatrics, Solid Tumor Program Director, Emory University School of Medicine, Aflac Cancer & Blood Disorders Center, Children's Healthcare of Atlanta | Atlanta, GA

Dr. Cash is an investigator with research interests focused on translating novel therapeutic agents and combinations into early phase clinical trials to improve the outcomes for children with relapsed/refractory solid tumors. He currently is an attending physician at the Aflac Cancer and Blood Disorders Center and serves as lead consultant for relapsed solid tumor patients. Previously Dr. Cash served as Interim Director of the Aflac Cancer and Blood Disorders Center Developmental Therapeutics Program, the largest phase I/II referral center in the Southeastern United States, and, since 2017, he has served as their institutional PI for the Children's Oncology Group (COG). Dr. Cash received his medical degree from the University of Alabama School of Medicine, completed his residency in pediatrics at the University of Arkansas for Medical Sciences and completed fellowship training in pediatric hematology/oncology at Emory University. He also holds a Master of Science in Clinical Research (MSCR) from Emory University.



## **Mary Beth Collins**

Parent Advocate, CAC2 | Bel Air, MD

Mary Beth Collins is the mother of a 26-year-old son who is a 24-year neuroblastoma survivor. As a parent advocate for most of those 24 years, her priority is long-term survivorship issues. She has been a strong voice for the impact of chemo-induced hearing loss, and helped advocate for the development of Pedmark<sup>®</sup>, a unique formulation of sodium thiosulfate (STS) that prevents cisplatin-induced ototoxicity in pediatric cancer patients. She serves as a parent advocacy consultant for Fennec Pharmaceuticals to help promote this newfound protection. Ms. Collins sits on the Survivorship Advisory Council for Children's Cancer Cause and has been a contributing member of CAC2's Advocacy & Awareness and Survivorship interest groups for the past 8 years. She is the author of the blog Survivorship Matters and serves as the Neuroblastoma Childhood Cancer Society Social Media Resource Liaison, providing support and recommendations to parents at various stages of treatment and survivorship for their children.

**Thank you to all of our 2023 speakers and panelists!**



**ZoAnn E. Dreyer, MD**

**Sidney L. and Donald F. Faust Professor in Pediatric Cancer Survivorship; Clinical Director, Long-Term Survivor Program; Professor, Department of Pediatrics, Section of Hematology-Oncology, Texas Children’s Hospital and Baylor College of Medicine | Houston, TX**

Dr. ZoAnn Dreyer is the Sidney L. and Donald F. Faust Professor in Pediatric Cancer Survivorship at Texas Children’s Hospital, Clinical Director of the Long-Term Survivor Clinic at Texas Children’s Cancer Center, and Professor, Department of Pediatric, Section of Hematology-Oncology at Baylor College of Medicine in Houston, Texas. Dr. Dreyer oversees The Passport for Care® application, an innovative healthcare initiative headed by faculty members of Baylor College of Medicine and Texas Children’s Cancer Center that addresses the need to provide survivors of childhood cancer with increased access to their medical information and healthcare guidelines. Additionally, she serves as the Medical Director for The Periwinkle Foundation’s Camp Periwinkle and is a board member of the Children’s Grand Adventure, the Candlelighters Childhood Cancer Family Alliance and the Snowdrop Foundation. Dr. Dreyer earned her bachelor’s degree and medical degree from the University of California, Davis and completed her internship, residency and postdoctoral fellowship at Baylor College of Medicine.



**Karen Effinger, MD, MS**

**Associate Professor of Pediatrics, Medical Director, Cancer Survivor Program, Emory University and Children’s Healthcare of Atlanta | Atlanta, GA**

Dr. Effinger completed her undergraduate degree at Northwestern University and medical school at New York Medical College. She then completed her general pediatrics residency and pediatric hematology/oncology fellowship at Stanford University, where she also earned her Master of Science in Epidemiology and Clinical Research. Dr. Effinger joined the Cancer Survivor Program at Emory University in December 2015 and currently serves as the Medical Director for the program, which has over 1000 survivor visits per year. On a national level, she chairs the Children’s Oncology Group Gastrointestinal/Hepatic/Dental and Urinary Tract Long Term Follow-Up Guidelines Taskforces, serves as the institutional principal investigator for the Childhood Cancer Survivor Study (CCSS), and co-chaired the Hepatotoxicity Working Group for the International Late Effects of Childhood Cancer Guideline Harmonization Group. Dr. Effinger’s research focuses on improving healthy lifestyles and continuation of care for survivors of childhood cancer.



**Elizabeth Fox, MD**

**Senior Vice President Clinical Research Administration, Associate Director of Clinical Research, St. Jude Children’s Research Hospital | Memphis, TN**

Dr. Fox leads regulatory and clinical trial operations as well clinical research prioritization and strategy at St Jude Children’s Research Hospital. Nationally, she is the vice-chair of Developmental Therapeutics for the Children’s Oncology Group and the Pediatric Early Phase Clinical Trials Network. Dr. Fox has expertise in quantitative clinical and pre-clinical pharmacology, pediatric clinical oncology, and clinical research and trial design including response and toxicity biomarker endpoint development. She applies an integrative approach to clinical drug development utilizing animal models, pre-clinical and clinical pharmacology to evaluate new therapies and novel trial designs to improve outcomes for children with catastrophic diseases.



**Susannah E. Koontz, PharmD, BCOP, FHOPA**

**Principal, Koontz Oncology Consulting LLC | Houston, TX**

Susannah Koontz, PharmD, BCOP, FHOPA is the Principal of Koontz Oncology Consulting LLC, where she serves as a consultant for clinical research and medical education in the fields of pediatric hematology/oncology and stem cell transplantation/cellular therapy. She works with healthcare professionals and members of the pharmaceutical industry to identify research priorities and to rationally apply cancer therapies in pediatric patients. In addition, she actively advocates on both the national and state levels for healthcare policy issues specific to cancer care. Prior to starting her firm in 2008, Dr. Koontz was the clinical pharmacy specialist for the Children’s Cancer Hospital at The University of Texas M.D. Anderson Cancer Center for over 10 years. During her tenure, she was a member of the Children’s Oncology Group (COG), served on the NCI’s Pediatric Central Institutional Review Board (CIRB) as a pharmacy representative and was the first pharmacist selected to join M.D. Anderson Cancer Center’s Clinical Ethics Committee.



# Speakers & Panelists, continued



## Theodore W. Laetsch, MD

Director, Developmental Therapeutics Program, Director, Very Rare Malignant Tumors Program, Associate Professor of Pediatrics, Children's Hospital of Philadelphia/University of Pennsylvania | Philadelphia, PA

Dr. Laetsch is an Associate Professor of Pediatrics at the University of Pennsylvania, chair of the Rare Tumors Committee for the Children's Oncology Group (COG), and director of the Developmental Therapeutics and Very Rare Malignant Tumors Programs, member of the Cellular Therapy Program, and coordinating PI for the Precision Medicine for High-Risk Pediatric Cancer Frontier Program at the Children's Hospital of Philadelphia (CHOP). He received his MD degree from the University of California, San Francisco. Dr. Laetsch completed his pediatrics residency at the University of Colorado/Children's Hospital Colorado and fellowship training in pediatric hematology/oncology at CHOP. Dr. Laetsch is a clinical trialist and has a number of leadership roles in precision medicine and cellular therapy trials. He serves on the NCI/COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Target Agent and Prioritization Committee and the NCI/COG Pediatric MATCH Leadership Committee



## Kaleigh Nix, MS, RD, CSO, LD

Clinical Nutritionist, Children's Healthcare of Atlanta | Atlanta, GA


Kaleigh Nix is an outpatient dietitian at Children's Healthcare of Atlanta. She completed her bachelor's degree, dietetic internship, and master's degree in nutrition at the University of Alabama. Kaleigh is a Certified Specialist in Oncology Nutrition and has worked with hematology, oncology, and bone marrow transplant patients in both pediatric and adult settings. She also currently works with pediatric liver, kidney, and heart transplant patients promoting healthy lifestyles post-transplant.



## Christina Salley, PhD

Director of Clinical Engagement & Outreach, Courageous Parents Network, Clinical Assistant Professor, Hassenfeld Children's Hospital & Department of Child & Adolescent Psychiatry, NYU School of Medicine | New York, NY

Dr. Salley is a pediatric psychologist with expertise in delivering support and intervention to parents and caregivers of children with complex medical needs. She is the Director of Clinician Engagement & Outreach at Courageous Parents Network. Dr. Salley is actively involved in the Society of Pediatric Psychology, Division 54 of the American Psychological Association. In addition to co-authoring "Standards of Psychosocial Care for Parents of Children with Cancer" (Pediatr Blood Cancer 2015;62:S632-S683), she has founded a professional group of pediatric psychologists who are committed to supporting parent caregivers through clinical intervention, research, education and outreach. She also collaborates with colleagues nationally and internationally on efforts to improve the illness experience for children and their families and publishes on these topics. Dr. Salley received her doctorate from The Ohio State University and is a Clinical Assistant Professor at Langone Health Grossman School of Medicine, New York University.



## Jack F. Shern, MD

Lasker Clinical Research Scholar, Pediatric Oncology Branch, National Cancer Institute | Bethesda, MD

As a physician scientist within the Pediatric Oncology Branch (POB) at the National Cancer Institute (NCI), Dr. Shern focuses his research on defining and developing precision therapies to target the genetic mutations that drive tumorigenesis. Dr. Shern utilizes single-cell sequencing to discover tumor subclonal populations that are responsible for relapse and refractory disease. Dr. Shern is actively engaged in the Children's Oncology Group (COG), where he works on pediatric soft tissue sarcomas to investigate the utility of using mutational information as biomarkers for the diagnosis and management of pediatric rhabdomyosarcoma. He received his medical degree from the Medical College of Georgia, completed his pediatric internship and residency training at the University of Chicago Comer Children's Hospital, and completed a combined Pediatric Hematology and Oncology Fellowship at the NCI-POB and Johns Hopkins University in Baltimore.



**Lee Troutman**  
Patient Survivor | Cumming, GA

After graduating from High School in 2020, Lee took online college classes and worked as a personal trainer. Lee’s passion is fitness, health, and helping others achieve their goals. In November 2021 Lee’s own health quickly spiraled out of control. Mono turned into sepsis, which turned into HLH and then lymphoma in the brain, spine, hip, liver, and ribs. Dropping from 190 pounds down to 103 pounds in a matter of months, Lee found himself fighting for his life. With a grim diagnosis Lee needed a bone marrow transplant for a chance to live. On May 24, 2022, he received that transplant from an anonymous donor. Lee is now 1 year post transplant and is thriving. Lee continues to focus on his health, having a positive mindset and is happy to be back in the gym. He is blessed to be alive!



**Alyssa Withee, RD, LD, CSP**  
Pediatric Dietician, Children’s Healthcare of Atlanta | Atlanta, GA

Alyssa Withee received her bachelor’s degree in Human Nutrition and Dietetics from Colorado State University. She has been a pediatric dietician at Children’s Healthcare of Atlanta for over 21 years. Ms. Withee has managed the nutrition care of patients with varying conditions during her career and has now taken on the rewarding role of providing care for the inpatient bone marrow transplant, oncology and hematology patients. Alyssa has been a Board-Certified Specialist in Pediatric Nutrition for over 15 years. In her free time, she enjoys spending time with her husband and three children, as well as hiking, baking, exercising, watching movies, reading, and spending time with friends.

**TRANSFORMING LIVES. REDEFINING POSSIBILITIES.**

**Jazz Pharmaceuticals is proud to sponsor the 2023 CAC2 Annual Summit**



Jazz Pharmaceuticals is a global biopharmaceutical company whose purpose is to innovate to transform the lives of patients and their families. We are dedicated to developing life-changing medicines for people with serious diseases — often with limited or no therapeutic options.



[www.jazzpharmaceuticals.com](http://www.jazzpharmaceuticals.com)

© 2023 Jazz Pharmaceuticals plc. All rights reserved. JPC-28298-0422



# Celebrating Our 10<sup>TH</sup> Anniversary IN THE Fight Against Childhood Cancer

## **We are thrilled to announce that CAC2 will celebrate its 10th anniversary during this year's Annual Summit with a special Celebration Dinner!**

The last decade has been full of unwavering commitment, hard work, and remarkable progress in the fight against childhood cancer. We are incredibly grateful to have had you with us every step of the way.

Therefore, during our dinner together, we will honor our past and present members and applaud the amazing triumphs we have accomplished over the years. We hope this celebration will help us look to the future with optimism and resolve as we return home and continue to impact the lives of children and families affected by pediatric cancers.

---

## **Though there are many CAC2 achievements worthy of praise over the past decade, we would like to showcase a few that continue to shine on an ongoing basis:**

- Advocating for increased funding for childhood cancer research.
- Engaging the community in advocacy campaigns to guarantee the passage of significant legislation.
- Encouraging collaboration among researchers, clinicians, and advocates.
- Participating in and hosting childhood cancer awareness events.
- Providing families with essential information and resources to navigate a pediatric cancer diagnosis.
- Raising awareness and addressing the challenges that childhood cancer survivors (ages 0-19), their caregivers, and their families face.
- Providing education and training opportunities.





Servier Pharmaceuticals is a privately held United States pharmaceutical company launched by the Sevier Group, a unique global organization operating in more than 150 countries and governed by a non-profit foundation.

**As a growing leader in oncology, Servier is committed to finding solutions that will address today's challenges.** Our goal is to serve our patients with the utmost treatment and care to improve the potential for survival.



Please visit [www.servier.us](http://www.servier.us) to learn more.



## Founded to Fight Neuroblastoma

Y-mAbs Therapeutics is a commercial-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based cancer treatments.

Our mission is to become the world leader in developing antibody-based cancer products that address clear unmet needs in pediatric and adult oncology.

**"My goal is to have these antibodies available worldwide, so that everyone has the same options my daughter and family had."**

—Thomas Gad, founder of Y-mAbs and father of Daniella, a high-risk neuroblastoma patient

Y-mAbs Therapeutics is proud to support the efforts of CAC2



To learn more about Y-mAbs, visit [ymabs.com](http://ymabs.com) or scan the QR code

© 2022 Y-mAbs Therapeutics, Inc. All rights reserved. NP-000110\_v2 05/23



# Giving kids with cancer MORE THAN HOPE Since 1998

[morganadamsfoundation.org](http://morganadamsfoundation.org)





# 2023 Annual Summit Sponsors and Supporters

## PRESENTING SPONSOR



## HOST SPONSOR AND OPENING PROGRAM RECEPTION SPONSOR



## PROGRAM BOOK SPONSOR



## LUNCH SPONSORS



## BREAKFAST SPONSORS



## BOB PINIEWSKI VOLUNTEER OF THE YEAR AWARD



## SUSTAINING SUPPORTERS

### GRANTS OR DONATIONS \$500+

- GlaxoSmithKline Foundation
- Jaime L. Howard
- Steven L. Pessagno
- Matt C. Taylor



### FRIENDS OF CAC2

#### GRANTS OR DONATIONS \$50 - \$500

- Jennifer Ivanovich
- Kim Lamb

## 2023-24 CATALYST SPONSORS

### 2023 WELCOME RECEPTION AT CUREFEST FOR CHILDHOOD CANCER



## HOPE PORTAL



## FOUNDATION MATCH





# No one treats more Georgia kids with cancer and blood disorders

**BEST**  
CHILDREN'S  
HOSPITALS

WORLD REPORT  
**USNews**

CANCER  
2022-23

## Nationally ranked in pediatric cancer treatment

Children's Healthcare of Atlanta treats more than 480 new cancer patients every year. Our pediatric cancer and blood disorders program is one of the largest in the nation, helping nearly 9,000 kids annually. We do it all, because nothing matters more than kids. To learn more, visit [choa.org/cancer](https://choa.org/cancer)



Children's is proud to support CAC2, because we are stronger and better, together.

## What science can do

### Oncology combination therapies

AstraZeneca is investigating combinations of biologic and small molecule therapies for the treatment of cancer. These combinations target the tumour directly and some help boost the body's own immune system to induce tumour cell death.



VEEVA ID: Z4-41462 Date of preparation: February 2022 Date of expiry: February 2024

ANDREW McDONOUGH



FOUNDATION<sup>®</sup>

[www.BePositive.org](http://www.BePositive.org)



**PROUD  
TO BE A  
CO-FOUNDER**



**CAC2**  
COALITION AGAINST  
CHILDHOOD CANCER



**FENNEC PHARMA**

**Helping kids hear the future**

Fennec Pharmaceuticals is a biotechnology company dedicated to improving the lives of children with cancer who experience hearing loss as a result of chemotherapy.

For more information visit  
[fennecpharma.com](http://fennecpharma.com)

Fennec<sup>®</sup> is a registered trademark of Fennec Pharmaceuticals Inc.  
©2023 Fennec Pharmaceuticals Inc. All rights reserved. FEN-1518-v1 03/23

# Day One is Proud to be Presenting Sponsor of the 2023 Coalition Against Childhood Cancer Summit

For the patients, parents, and families facing a pediatric cancer diagnosis — and for the healthcare providers they put their trust in for their child's care — the treatment journey begins with “The Day One Talk”.

To learn more about The Day One Talk – the inspiration behind our name and our mission – visit [TheDayOneTalk.com](https://TheDayOneTalk.com) or scan the QR code below.



©2023 Day One Biopharmaceuticals, Inc. PLGG-US-0109 04/23

The Day One logo is a registered trademark of Day One Biopharmaceuticals, Inc. All rights reserved.